(Q30234836)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28403729%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

title

Cost-effectiveness of vildagliptin for people with type 2 diabetes mellitus in Brazil; findings and implications (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28403729%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

1 reference

1 reference

Gustavo Laine Araújo de Oliveira

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28403729%20AND%20SRC:MED&resulttype=core&format=json

Francisco de Assis Acurcio

17 March 2020

object named as

Francisco de Assis Acurcio

4

1 reference

ORCID Public Data File 2021

author name string

Augusto Afonso Guerra Júnior

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28403729%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

Brian Godman

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28403729%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

publication date

22 February 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28403729%20AND%20SRC:MED&resulttype=core&format=json

Expert Review of Pharmacoeconomics & Outcomes Research

17 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28403729%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

volume

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28403729%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

page(s)

109-119

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28403729%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28403729%20AND%20SRC:MED&resulttype=core&format=json

Factors associated with glycemic control among adult patients with type 2 diabetes mellitus: a cross-sectional survey in Ethiopia

17 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1080%2F14737167.2017.1292852

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737167.2017.1292852

Prevention and treatment of diabetic renal disease in type 2 diabetes: the BENEDICT study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737167.2017.1292852

MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737167.2017.1292852

Are new models needed to optimize the utilization of new medicines to sustain healthcare systems?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737167.2017.1292852

Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 Diabetes: A Systematic Review and Meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737167.2017.1292852

Cardiovascular Outcomes of Dipeptidyl Peptidase-4 Inhibitors in Elderly Patients With Type 2 Diabetes: A Nationwide Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737167.2017.1292852

Antidiabetic treatment with gliptins: focus on cardiovascular effects and outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737167.2017.1292852

Cardiovascular and heart failure safety profile of vildagliptin: a meta-analysis of 17 000 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737167.2017.1292852

Cardiovascular risk with DPP-4 inhibitors: latest evidence and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737167.2017.1292852

Cardiovascular Effects of Glucose-lowering Therapies for Type 2 Diabetes: New Drugs in Perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737167.2017.1292852

Dipeptidyl peptidase-4 inhibitors and protection against stroke: A systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737167.2017.1292852

The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737167.2017.1292852

Medication adherence in type 2 diabetes patients: study of patients in Alimosho General Hospital, Igando, Lagos, Nigeria

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737167.2017.1292852

Adherence to therapies in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737167.2017.1292852

Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737167.2017.1292852

Systematic review and meta-analysis of vildagliptin for treatment of type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737167.2017.1292852

Insulin glargine in a Brazilian state: should the government disinvest? An assessment based on a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737167.2017.1292852

Markov models in medical decision making: a practical guide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737167.2017.1292852

Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737167.2017.1292852

Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737167.2017.1292852

A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737167.2017.1292852

Effectiveness and tolerability of second-line therapy with vildagliptin vs. other oral agents in type 2 diabetes: a real-life worldwide observational study (EDGE)

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737167.2017.1292852

Drug utilization, safety, and effectiveness of exenatide, sitagliptin, and vildagliptin for type 2 diabetes in the real world: data from the Italian AIFA Anti-diabetics Monitoring Registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737167.2017.1292852

A New Reimbursement System for Innovative Pharmaceuticals Combining Value-Based and Free Market Pricing

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737167.2017.1292852

NICE guidance: a comparative study of the introduction of the single technology appraisal process and comparison with guidance from Scottish Medicines Consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737167.2017.1292852

Reimbursement Decisions for Pharmaceuticals in Sweden: The Impact of Disease Severity and Cost Effectiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737167.2017.1292852

Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737167.2017.1292852

Cost-effectiveness of metformin plus vildagliptin compared with metformin plus sulphonylurea for the treatment of patients with type 2 diabetes mellitus: a Portuguese healthcare system perspective.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737167.2017.1292852

UKPDS outcomes model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year United Kingdom Prospective Diabetes Study: UKPDS 82.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737167.2017.1292852

Cost effectiveness of dipeptidyl peptidase-4 inhibitors for type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737167.2017.1292852

The place of DPP-4 inhibitors in the treatment algorithm of diabetes type 2: a systematic review of cost-effectiveness studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737167.2017.1292852

Cost-effectiveness of dapagliflozin versus DPP-4 inhibitors as an add-on to Metformin in the Treatment of Type 2 Diabetes Mellitus from a UK Healthcare System Perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737167.2017.1292852

Novel Therapeutics for Diabetes: Uptake, Usage Trends, and Comparative Effectiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737167.2017.1292852

10.1080/14737167.2017.1292852

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28403729%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

1 reference